The expression of syndecan-1, syndecan-4 and decorin in healthy human breast tissue during the menstrual cycle.
BACKGROUND
In order to unravel the interactions between the epithelium and the extra cellular matrix (ECM) in breast tissue progressing to cancer, it is necessary to understand the relevant interactions in healthy tissue under normal physiologic settings. Proteoglycans in the ECM play an important role in the signaling between the different tissue compartments. The proteoglycan decorin is abundant in the breast stroma. Decreased expression in breast cancer tissue is a sign of a poor tumor prognosis. The heparane sulphate proteoglycans syndecan-1 and syndecan-4 promote the integration of cellular adhesion and proliferation. The aim of this study was to investigate the gene expression and location of decorin, syndecan-1 and syndecan-4 in the healthy breast during the menstrual cycle.


METHODS
Tissue from healthy women undergoing breast reduction plastic surgery was examined using immunohistochemistry (n = 38) and Real-Time RT-PCR (n = 20). Both parous and nulliparous women were eligible and the mean age of the women was 34(+/- 10 years) with regular menstrual cycles (28 +/- 7 days). None of the women had used hormonal treatment the last three months. The women were randomized to needle biopsy two months before the operation in the follicular or luteal menstrual phase and for another biopsy at the operation in the opposite phase. Serum samples were obtained to characterize the menstrual phase. The Wilcoxon signed rank test and Mann Whitney test were used for statistical analyses.


RESULTS
By real time-RT-PCR the gene signal for all three proteoglycans; decorin (p = 0.02) and syndecan-1 (p = 0.03) and syndecan-4 (p = 0.02) was significantly lower among parous women in the luteal phase than in the follicular phase. Immunohistochemistry confirmed the identification of the proteins but no significant difference between menstrual phases was observed. Serum samples verified the menstrual phase.


CONCLUSIONS
Our study shows, for the first time in the healthy breast, a significantly lower expression of the genes for the three proteoglycans, decorin, syndecan-1 and syndecan-4 in the luteal phase during the menstrual cycle. These changes were registered under normal physiologic conditions. Since ECM molecules appear to be involved in tumor progression, these findings in the normal breast could constitute a base for further studies in women receiving hormonal therapy or those with breast cancer.
Hallberg
Gunilla
G
Department of Women's and Children's Health, Karolinska Institute, Solna S-171 76 Stockholm, Sweden. gunvor.ekman-ordeberg@ki.se.
Andersson
Eva
E
Naessén
Tord
T
Ordeberg
Gunvor Ekman
GE
D000328:Adult; D044963:Biopsy, Fine-Needle; D058575:Decorin; D016326:Extracellular Matrix Proteins / Q000235:genetics* / Q000378:metabolism; D005260:Female; D015870:Gene Expression / Q000502:physiology; D006262:Health; D006801:Humans; D007150:Immunohistochemistry; D042361:Mammary Glands, Human / Q000378:metabolism* / Q000473:pathology; D008597:Menstrual Cycle / Q000235:genetics* / Q000378:metabolism; D011509:Proteoglycans / Q000235:genetics* / Q000378:metabolism; D020133:Reverse Transcriptase Polymerase Chain Reaction; D053668:Syndecan-1 / Q000235:genetics* / Q000378:metabolism; D053671:Syndecan-4 / Q000235:genetics* / Q000378:metabolism; D055815:Young Adult
C546878:DCN protein, human; D058575:Decorin; D016326:Extracellular Matrix Proteins; D011509:Proteoglycans; C508241:SDC1 protein, human; C508304:SDC4 protein, human; D053668:Syndecan-1; D053671:Syndecan-4
Histochem Cell Biol. 2002 Sep;118(3):221-30
12271358
Am J Surg Pathol. 1986 Jun;10(6):382-93
3717495
Annu Rev Biochem. 1999;68:729-77
10872465
Breast Cancer Res. 2003;5(3):130-5
12793893
Clin Cancer Res. 2003 Jan;9(1):207-14
12538471
Anticancer Res. 2007 Sep-Oct;27(5A):3045-50
17970043
Breast Cancer Res. 2009;11(1):R7
19187537
Cell Tissue Res. 1992 Apr;268(1):167-77
1499048
Breast Cancer Res. 2003;5(4):208-15
12817994
Breast Cancer Res. 2009;11(2):102
19344495
Exp Cell Res. 2004 Oct 15;300(1):234-47
15383330
Oncogene. 2005 Feb 3;24(6):1104-10
15690056
Breast Cancer Res Treat. 2006 Jul;98(1):91-8
16636895
Cancer. 2003 Aug 1;98(3):474-83
12879463
Acta Physiol Scand. 2000 Mar;168(3):385-92
10712576
Am J Pathol. 2008 Sep;173(3):844-55
18688028
Climacteric. 2006 Aug;9(4):277-82
16857657
Fertil Steril. 2007 Jan;87(1):121-6
17113089
Differentiation. 1990 Feb;42(3):199-207
1692795
Breast Cancer Res. 2005;7(1):33-6
15642180
Br J Surg. 1996 Aug;83(8):1037-46
8869300
Mod Pathol. 2002 Dec;15(12):1348-56
12481017
Fertil Steril. 2007 Mar;87(3):657-63
17123519
Pharmacol Res. 1995 Dec;32(6):327
8736481
Biochemistry (Mosc). 2007 Sep;72(9):1016-20
17922662
Eur J Cancer. 2004 Jun;40(9):1373-82
15177497